On January 26, 2021, the Ninth U.S. Circuit Court of Appeals affirmed the dismissal of a putative securities fraud class action, holding that: (i) the plaintiffs could not plead loss causation for an alleged misstatement...more
On June 10, 2020, the Ninth Circuit affirmed the dismissal of a putative securities fraud class action in a potentially significant decision for securities defendants, particularly those in the pharmaceutical, biotech and...more
6/16/2020
/ Biotechnology ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Inflated Projections ,
Medical Devices ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Putative Class Actions ,
Scienter ,
Securities Fraud ,
Securities Litigation